Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
6129 participants
OBSERVATIONAL
2013-10-31
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Uremic Toxin Removal and Hemodynamics in Long-hour Hemodialysis and Hemodiafiltration
NCT01328119
Is Myocardial Stunning Induced by Continuous Renal Replacement Therapy a Reality in Critically Ill Patients?
NCT05209230
Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis
NCT00004285
Study Evaluating the Pronostic Value of Vascular Refilling Rate on Mortality in Chronic Kidney Disease Patients on Dialysis
NCT04810338
Association of Survival in Impact of Ultrafiltration Rates in Hemodialysis Patients
NCT03471299
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hemodialysis patients
Patients \> 18y hemodialysis for at least 6 months at any center of Spain Fresenius Medical Care (FMC) meeting the inclusion criteria.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* \> six months on hemodialysis
* Receiving 3 sessions of dialysis per week
* Having 5 or more valid measures of Kt during the month
Exclusion Criteria
* Liver cirrhosis
* Neoplasms
* Chronic immunosuppression or use of anti-inflammatory
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NephroCare Spain
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rosa Ramos
MD, Ph
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Francesc Maduell, MD, Ph
Role: PRINCIPAL_INVESTIGATOR
Servei Nefrologia, ICNU, Hospital Clínic.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NephroCare Spain
Madrid, Madrid, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
QM-RR-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.